Cargando…

Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC) accounts for 30–51% of all BCs. How to precisely assess the response to neoadjuvant therapy in this heterogenous tumor is currently unanswered. With the advance in multi-omics, refining the molecular subtyping other t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoping, Lin, Zhiquan, Yu, Qihe, Qiu, Chaoran, Lai, Chan, Huang, Hui, Zhang, Yiwen, Zhang, Weibin, Zhu, Jintao, Huang, Xin, Li, Weiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005989/ https://www.ncbi.nlm.nih.gov/pubmed/36915818 http://dx.doi.org/10.21037/gs-22-729

Ejemplares similares

A cholesterogenic gene signature for predicting the prognosis of young breast cancer patients
por: Li, Xiaoping, et al.
Publicado: (2022)

Comprehensive analysis reveals potential hub genes and therapeutic drugs in an acquired lymphedema model
por: Qiu, Chaoran, et al.
Publicado: (2022)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Prognostic model of invasive ductal carcinoma of the breast based on differentially expressed glycolysis-related genes
por: Li, Xiaoping, et al.
Publicado: (2020)

A Signature of Autophagy-Related Long Non-coding RNA to Predict the Prognosis of Breast Cancer
por: Li, Xiaoping, et al.
Publicado: (2021)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Development and validation of a prognostic nomogram for early-onset colon cancer
por: Yu, Chaoran, et al.
Publicado: (2019)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Construction and validation of a novel apoptosis-associated prognostic signature related to osteosarcoma metastasis and immune infiltration
por: Fu, Yucheng, et al.
Publicado: (2022)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
por: Wu, Xueying, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
por: Shang, Jiuyan, et al.
Publicado: (2023)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

A generalized non-linear model predicting efficacy of neoadjuvant therapy in HER2+ breast cancer
por: Wang, Yusong, et al.
Publicado: (2023)

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
por: Huang, Haijun, et al.
Publicado: (2023)

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
por: Zhu, Siji, et al.
Publicado: (2023)

Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer
por: Liu, Qian, et al.
Publicado: (2023)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
por: Chen, Mengdi, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value
por: Wang, Changjun, et al.
Publicado: (2020)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
por: Yang, Tao, et al.
Publicado: (2022)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vv34vse5qic6p4jjgq7br90f6e